Text Size
36 studies found for:    " September 29, 2010":" October 29, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Active, not recruiting Multi-vitamins, HAART and HIV/AIDS in Uganda
Condition: HIV/AIDS
Intervention: Dietary Supplement: Multivitamin supplements B,C and E
2 Recruiting A Study to Assess the Efficacy of Raltegravir, Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145 AM1) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)
Condition: HIV-1 Infection
Intervention: Drug: Raltegravir
3 Recruiting HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir
Conditions: Chronic HIV Infection;   HCV Coinfection
Intervention: Drug: Fosamprenavir
4 Recruiting Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
Condition: HIV
Intervention: Drug: Tenofovir/emtricitabine and raltegravir
5 Active, not recruiting Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT)
Conditions: HIV Infection;   Acquired Immunodeficiency Syndrome
Interventions: Drug: Protease Inhibitor;   Drug: Standard-of-care Antiretroviral therapy
6 Active, not recruiting Use of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risks
Conditions: HIV Infections;   Heart Disease
Interventions: Drug: Rosuvastatin 10 mg. daily for 96 weeks;   Drug: Placebo
7 Completed Non-virologic Methods to Diagnose Treatment Eligibility in HIV-exposed Infants
Condition: HIV Infections
Intervention:
8 Completed Safety and Immunogenicity Study of Ad26-ENVA and Ad35-ENV HIV Vaccines in Healthy HIV-uninfected Adults
Condition: HIV Infections
Interventions: Biological: Ad35-ENV vaccine;   Biological: Ad26.ENVA.01 vaccine;   Biological: Placebo Control
9 Recruiting Study to Improve Survival Among HIV-Exposed Infants in Botswana
Conditions: HIV Infections;   Neutropenia;   Anemia
Interventions: Drug: cotrimoxazole prophylaxis;   Drug: cotrimoxazole placebo;   Behavioral: exclusive breastfeeding until 6 months of age;   Behavioral: breastfeeding for 12 months
10 Completed
Has Results 		Drug Use Investigation On Zithromac (Azithromycin) In HIV Patients
Condition: HIV Infection
Intervention: Drug: Azithromycin
11 Withdrawn Depot Contraception With and Without Lopinavir/Ritonavir
Condition: HIV Infection
Intervention: Drug: DMPA
12 Completed Acceptability Study of Vaginal Films for HIV Prevention
Conditions: HIV Infections;   Anti-Infective Agents
Intervention: Other: No intervention (not applicable)
13 Recruiting Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)
Conditions: HIV Infection;   Bone Loss;   Osteopenia;   Osteoporosis
Intervention: Drug: Zoledronic acid
14 Unknown † Epidemiology of Papillomavirus Infection (HPV) on Infected Women by Human Immunodeficience Virus (HIV) in West Indies and French Guiana.
Conditions: 1- Women;   2- HIV Infection;   3- Followed in West Indies and French Guiana for His Infection;   4- Acceptance of the Use of Nadis® Medical Files
Intervention: Other: Biological Sample collection
15 Completed Efficacy and Safety of GSK Biologicals HIV Vaccine in Antiretroviral Therapy (ART)-naïve HIV-1 Infected Persons
Condition: Infection, Human Immunodeficiency Virus
Interventions: Biological: GSK Biologicals HIV Vaccine 732462;   Drug: Placebo
16 Active, not recruiting Pharmacokinetic Interactions Between an Herbal Medicine (African Potato) and Antiretroviral Agents (Lopinavir/Ritonavir)
Conditions: Drug Interactions;   Human Immunodeficiency Virus
Intervention: Drug: Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)
17 Terminated Dose-finding Study of GSK2248761 in Antiretroviral Therapy-Naive Subjects (SIGNET)
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK2248761 100 mg once daily;   Drug: GSK2248761 200 mg once daily;   Drug: Efavirenz 600 mg once daily
18 Active, not recruiting A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
Condition: Infection, Human Immunodeficiency Virus I
Interventions: Drug: GSK1349572;   Drug: raltegravir;   Other: Placebo;   Other: ABC/3TC;   Other: TDF/FTC
19 Recruiting Hydroxychloroquine for Discordant CD4 Responders on Highly Active Antiretroviral Therapy (HAART)
Condition: HIV Infection
Intervention: Drug: Hydroxychloroquine
20 Completed Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires
Conditions: Malaria;   Schistosomiasis;   Hiv Infection
Intervention:
To Top

Previous Page Studies Shown (1-20) Next Page (21-36) Show next page of results
† Indicates status has not been verified in more than two years